Pegloticase and Allopurinol Interaction

Understanding the Pegloticase and Allopurinol Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Pegloticase belongs to the Recombinant Uricase class and Allopurinol belongs to the Xanthine Oxidase Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Allopurinol can hide changes in your blood levels that warn doctors of a possible severe allergic reaction to pegloticase. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Pegloticase has 2 total documented interactions on file in this dataset, and Allopurinol has 10. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Stop taking allopurinol before starting pegloticase and do not take it again while you are on treatment. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pegloticase or Allopurinol based on a web page, speak with your prescriber or pharmacist before making any change.